GLP-1 agonists may be able to treat addiction, prevent Alzheimer’s, and more. KEY TAKEAWAYS By Kristin Houser If the COVID-19 vaccines were the most significant FDA approvals of the 2020s so far, GLP-1 agonists to treat obesity are a strong runner up. Though these drugs have been used to treat type 2 diabetes for nearly two decades, it wasn’t until 2021 that the FDA approved one of them — Novo Nordisk’s Wegovy (semaglutide) — as a treatment for obesity. Clinical trials showed that people lost 10-20% of their body weight. This was huge. An estimated 42% of adults in America are classified as obese, which … Continue reading Are weight-loss meds the next wonder drugs?